Published in Hepatology on August 06, 2013
Expanded criteria donors. Clin Liver Dis (2014) 0.79
The corrected donor age for hepatitis C virus-infected liver transplant recipients. Liver Transpl (2015) 0.79
Donor Factors Including Donor Risk Index Predict Fibrosis Progression, Allograft Loss, and Patient Survival following Liver Transplantation for Hepatitis C Virus. J Clin Exp Hepatol (2015) 0.75
Key donor factors associated with graft loss among liver transplant recipients with human immunodeficiency virus. Clin Transplant (2016) 0.75
Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med (2008) 57.29
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature (2009) 13.99
Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med (2004) 11.46
Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med (2004) 8.12
Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant (2006) 8.03
Burden of liver disease in the United States: summary of a workshop. Hepatology (2002) 4.00
Liver transplantation in the United States, 1999-2008. Am J Transplant (2010) 3.92
Hepatitis C infection in African Americans: its natural history and histological progression. Am J Gastroenterol (2002) 2.09
An examination of liver offers to candidates on the liver transplant wait-list. Gastroenterology (2012) 2.03
Racial differences in liver transplantation outcomes in the MELD era. Am J Gastroenterol (2008) 1.79
The effect of donor race on the survival of Black Americans undergoing liver transplantation for chronic hepatitis C. Liver Transpl (2009) 1.64
Consistent beneficial effects of killer cell immunoglobulin-like receptor 2DL3 and group 1 human leukocyte antigen-C following exposure to hepatitis C virus. Hepatology (2010) 1.59
Recipient-donor race mismatch for African American liver transplant patients with chronic hepatitis C. Liver Transpl (2012) 1.54
Outcomes of donor evaluation in adult-to-adult living donor liver transplantation. Hepatology (2007) 1.31
Impact of the donor risk index on the outcome of hepatitis C virus-positive liver transplant recipients. Liver Transpl (2009) 1.29
Indications for liver transplantation. Gastroenterology (2008) 1.28
Correlates of hepatitis C virus (HCV) RNA negativity among HCV-seropositive blood donors. Transfusion (2006) 1.22
Fibrosis progression in African Americans and Caucasian Americans with chronic hepatitis C. Clin Gastroenterol Hepatol (2008) 1.19
Impact of donor age and year of transplantation on graft and patient survival following liver transplantation for hepatitis C virus. Transplantation (2006) 1.19
The course of posttransplant hepatitis C infection: comparative impact of donor and recipient source of the favorable IL28B genotype and other variables. Transplantation (2012) 1.08
Donor age affects fibrosis progression and graft survival after liver transplantation for hepatitis C. Transplantation (2004) 1.07
Hepatitis C virus infection in African Americans. Clin Infect Dis (2005) 1.06
Modeling hepatic fibrosis in African American and Caucasian American patients with chronic hepatitis C virus infection. Hepatology (2006) 0.99
Outcomes in adult and pediatric liver transplantation among various ethnic groups. Transplant Proc (2007) 0.98
Human leukocyte antigen class II associations with hepatitis C virus clearance and virus-specific CD4 T cell response among Caucasians and African Americans. Hepatology (2008) 0.97
Differential effects of donor and recipient IL28B and DDX58 SNPs on severity of HCV after liver transplantation. J Hepatol (2013) 0.90
Ethnic and geographical differences in HLA associations with the outcome of hepatitis C virus infection. Virol J (2009) 0.87
Racial differences in fibrosis progression after HCV-related liver transplantation. Transplantation (2012) 0.82
Hepatitis C treatment outcomes of African Americans following liver transplantation. Transplant Proc (2002) 0.81
Graft loss and racial mismatch in hepatitis C virus-positive liver transplant patients. Liver Transpl (2012) 0.77
Treatment of patients infected with chronic hepatitis C genotype 2 and 3: more data, more questions? Hepatology (2009) 0.77
Telaprevir for previously treated chronic HCV infection. N Engl J Med (2010) 8.33
Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology (2006) 4.90
Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology (2008) 4.26
Burden of liver disease in the United States: summary of a workshop. Hepatology (2002) 4.00
Sexual transmission of hepatitis C virus among monogamous heterosexual couples: the HCV partners study. Hepatology (2013) 3.35
An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med (2014) 3.04
Serum sodium predicts mortality in patients listed for liver transplantation. Hepatology (2005) 2.63
Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology (2006) 2.62
A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation. Liver Transpl (2005) 2.56
Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy. Liver Transpl (2013) 2.53
Increasing disparity in waitlist mortality rates with increased model for end-stage liver disease scores for candidates with hepatocellular carcinoma versus candidates without hepatocellular carcinoma. Liver Transpl (2012) 2.32
Risk prediction of hepatocellular carcinoma in patients with cirrhosis: the ADRESS-HCC risk model. Cancer (2014) 2.26
Expanded criteria donors for kidney transplantation. Am J Transplant (2003) 2.25
Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease. Hepatology (2005) 2.24
Developmental context determines latency of MYC-induced tumorigenesis. PLoS Biol (2004) 2.05
An examination of liver offers to candidates on the liver transplant wait-list. Gastroenterology (2012) 2.03
National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant (2004) 2.01
Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology (2014) 1.91
PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. Liver Transpl (2011) 1.85
Liver-specific loss of beta-catenin blocks glutamine synthesis pathway activity and cytochrome p450 expression in mice. Hepatology (2006) 1.69
Report of the first international liver transplantation society expert panel consensus conference on renal insufficiency in liver transplantation. Liver Transpl (2009) 1.69
Sirolimus prolongs recovery from delayed graft function after cadaveric renal transplantation. Am J Transplant (2003) 1.65
Laboratory test results after living liver donation in the adult-to-adult living donor liver transplantation cohort study. Liver Transpl (2011) 1.59
Alcohol use and hepatitis C. Hepatology (2002) 1.55
Multicenter evaluation of the performance characteristics of the bayer VERSANT HCV RNA 3.0 assay (bDNA). J Clin Microbiol (2004) 1.55
Recipient-donor race mismatch for African American liver transplant patients with chronic hepatitis C. Liver Transpl (2012) 1.54
Kidney and liver transplantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy study. Transplantation (2003) 1.54
Time to transplantation as a predictor of hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl (2014) 1.54
Hepatic steatosis at 1 year is an additional predictor of subsequent fibrosis severity in liver transplant recipients with recurrent hepatitis C virus. Liver Transpl (2011) 1.52
Factors influencing liver transplant length of stay at two large-volume transplant centers. Liver Transpl (2009) 1.48
Report of the Crystal City meeting to maximize the use of organs recovered from the cadaver donor. Am J Transplant (2002) 1.44
Offer patterns of nationally placed livers by donation service area. Liver Transpl (2013) 1.42
Liver-specific loss of beta-catenin results in delayed hepatocyte proliferation after partial hepatectomy. Hepatology (2007) 1.40
Trends in waiting list registration for liver transplantation for viral hepatitis in the United States. Gastroenterology (2009) 1.35
Outcomes of donor evaluation in adult-to-adult living donor liver transplantation. Hepatology (2007) 1.31
Specific human leukocyte antigen class I and II alleles associated with hepatitis C virus viremia. Hepatology (2010) 1.28
A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. Hepatology (2013) 1.21
Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection. Hepatology (2012) 1.20
Limitations of conventionally derived chronic liver disease mortality rates: Results of a comprehensive assessment. Hepatology (2008) 1.17
Prospective analysis of depression during peginterferon and ribavirin therapy of chronic hepatitis C: results of the Virahep-C study. Am J Gastroenterol (2009) 1.16
Hospitalization rates before and after adult-to-adult living donor or deceased donor liver transplantation. Ann Surg (2010) 1.13
New onset diabetes mellitus after liver transplantation: the critical role of hepatitis C infection. Liver Transpl (2004) 1.11
The changing epidemiology and natural history of hepatitis C virus infection. Clin Liver Dis (2006) 1.11
Linking the US transplant registry to administrative claims data: expanding the potential of transplant research. Med Care (2007) 1.09
Hepatitis C virus-infected women have a higher risk of advanced fibrosis and graft loss after liver transplantation than men. Hepatology (2011) 1.09
Laparoscopic procurement of kidneys with multiple renal arteries is associated with increased ureteral complications in the recipient. Am J Transplant (2005) 1.08
Allocation policy for hepatocellular carcinoma in the MELD era: room for improvement? Liver Transpl (2007) 1.08
Influence of cannabis use on severity of hepatitis C disease. Clin Gastroenterol Hepatol (2008) 1.08
Cancer screening, reproductive history, socioeconomic status, and anticipated cancer-related behavior among Hmong adults. Asian Pac J Cancer Prev (2006) 1.07
Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. Am J Transplant (2005) 1.06
Validating posttransplant hepatocellular carcinoma recurrence data in the United Network for Organ Sharing database. Liver Transpl (2013) 1.02
Center competition and outcomes following liver transplantation. Liver Transpl (2013) 1.01
Treatment of hepatitis C in liver transplant patients: interferon out, direct antiviral combos in. Liver Transpl (2015) 1.01
End stage polycystic kidney disease: indications and timing of native nephrectomy relative to kidney transplantation. J Urol (2005) 1.00
Peginterferon pharmacokinetics in African American and Caucasian American patients with hepatitis C virus genotype 1 infection. Clin Gastroenterol Hepatol (2008) 1.00
Management of hepatitis B in liver transplant recipients. J Viral Hepat (2007) 0.99
Outcomes after liver transplantation for patients with hepatocellular carcinoma and a low risk of dropout from the transplant waiting list. Liver Transpl (2014) 0.97
Characteristics and management of patients with chronic hepatitis B in an integrated care setting. Dig Dis Sci (2014) 0.96
Management of posttransplant hepatitis C infection. Curr Opin Organ Transplant (2010) 0.94
BKV in simultaneous pancreas-kidney transplant recipients: a leading cause of renal graft loss in first 2 years post-transplant. Am J Transplant (2005) 0.93
Use of living donor liver transplantation varies with the availability of deceased donor liver transplantation. Liver Transpl (2012) 0.93
Sex and hepatitis C. Am J Gastroenterol (2005) 0.92
Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infection. Gastroenterology (2013) 0.92
Hepatitis B virus quasispecies in hepatic and extrahepatic viral reservoirs in liver transplant recipients on prophylactic therapy. Liver Transpl (2011) 0.92
Projected future increase in aging hepatitis C virus-infected liver transplant candidates: a potential effect of hepatocellular carcinoma. Liver Transpl (2012) 0.91
Early graft function after living donor kidney transplantation predicts rejection but not outcomes. Am J Transplant (2004) 0.91
Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol (2005) 0.91
The option of HBIG-free prophylaxis against recurrent HBV. J Hepatol (2012) 0.90
Rituximab therapy for pure red cell aplasia due to anti-epoetin antibodies in a woman treated with epoetin-alfa: a case report. J Med Case Rep (2009) 0.90
Increased rejection in living unrelated versus living related kidney transplants does not affect short-term function and survival. Transplantation (2004) 0.89
Protective antibody levels and dose requirements for IV 5% Nabi Hepatitis B immune globulin combined with lamivudine in liver transplantation for hepatitis B-induced end stage liver disease. Liver Transpl (2006) 0.88
Risk of advanced fibrosis with grafts from hepatitis C antibody-positive donors: a multicenter cohort study. Liver Transpl (2012) 0.88
Telaprevir- and Boceprevir-based Triple Therapy for Hepatitis C in Liver Transplant Recipients With Advanced Recurrent Disease: A Multicenter Study. Transplantation (2015) 0.88
Progression of biopsy-measured liver fibrosis in untreated patients with hepatitis C infection: non-Markov multistate model analysis. PLoS One (2011) 0.88
Clinical evaluation (Phase I) of a human monoclonal antibody against hepatitis C virus: safety and antiviral activity. J Hepatol (2006) 0.87
Organ donors with malignant gliomas: an update. Am J Transplant (2004) 0.87
Human immunodeficiency virus and liver transplantation: Hepatitis C is the last hurdle. Hepatology (2015) 0.86
Sofosbuvir, simeprevir, and ribavirin for the treatment of hepatitis C virus recurrence in human immunodeficiency virus/hepatitis C virus-coinfected liver transplant recipients. Liver Transpl (2015) 0.86
Transplantation of islets transduced with CTLA4-Ig and TGFbeta using adenovirus and lentivirus vectors. Transpl Immunol (2004) 0.86
A Comparison of Muscle Function, Mass, and Quality in Liver Transplant Candidates: Results From the Functional Assessment in Liver Transplantation Study. Transplantation (2016) 0.85
Complementary and alternative medicine use in chronic liver disease patients. J Clin Gastroenterol (2010) 0.85
Combined effects of recipient age and model for end-stage liver disease score on liver transplantation outcomes. Transplantation (2014) 0.85
The epidemiology and clinical characteristics of patients with newly diagnosed alcohol-related liver disease: results from population-based surveillance. J Clin Gastroenterol (2010) 0.85
Hepatitis C genotype influences post-liver transplant outcomes. Transplantation (2015) 0.85
How can we define expanded criteria for liver donors? J Hepatol (2006) 0.85
Management of lymphoceles after renal transplantation: laparoscopic versus open drainage. J Urol (2003) 0.84
Ending vertical transmission of hepatitis B: the third trimester intervention. Hepatology (2014) 0.84
Effects of ethnicity and socioeconomic status on survival and severity of fibrosis in liver transplant recipients with hepatitis C virus. Liver Transpl (2012) 0.83
Hepatitis C direct antiviral drugs and hepatic decompensation in patients with advanced cirrhosis: culprit or innocent bystander? Dig Dis Sci (2015) 0.83
Organ donors with positive viral serology or malignancy: risk of disease transmission by transplantation. Transplantation (2002) 0.82
Peri-operative hyperglycemia is associated with delayed graft function in deceased donor renal transplantation. Clin Transplant (2013) 0.82
Sirolimus delays recovery of rat kidney transplants after ischemia-reperfusion injury. Transplantation (2003) 0.82
Monocyte activation by interferon α is associated with failure to achieve a sustained virologic response after treatment for hepatitis C virus infection. J Infect Dis (2013) 0.82
Solid organ transplants in HIV-infected patients. Curr HIV/AIDS Rep (2013) 0.81
Renal outcomes of simultaneous liver-kidney transplantation compared to liver transplant alone for candidates with renal dysfunction. Clin Transplant (2014) 0.81
Management of the liver transplant patient. Expert Rev Gastroenterol Hepatol (2009) 0.81
An uncomfortable silence em leader while we all search for a better reporter gene in adult stem cell biology. Hepatology (2004) 0.81
Tolerance: is it achievable in pediatric solid organ transplantation? Pediatr Clin North Am (2010) 0.81